Dr. Tiny Nair : New Thrombolytic Agents Better Than The Older Options
Tenecteplase has many advantages over streptokinase, but is also ten times pricier.
881 Total Views
Supported by an Unrestricted Educational Grant from
Dr. Tiny Nair
Chief Consultant Cardiologist
PRS Hospital, Kerala
“Tenecteplase, a new thrombolytic agent is fibrin specific and has ease of administration, but it is ten times pricier than the old streptokinase, which is not fibrin specific but cheap and easily available,” Dr. Tiny Nair tells Dr. Rishi Jain in an interview.But if this one-time cost gives better left ventricular function and a better quality life, then the advantages of tenecteplase over streptokinase are worth it- better patency rate, more TIMI 2 and 3 flow and quick action.“Tenecteplase would be definitely preferred over streptokinase if cost factor is eliminated. Therefore, our aim should be to buffer the cost difference between the two.”Dr. Nair also recommends thrombolysis in cases where door-to-balloon time exceeds 90 minutes.